SG11201805941WA - Tgfbeta 2 antibodies - Google Patents
Tgfbeta 2 antibodiesInfo
- Publication number
- SG11201805941WA SG11201805941WA SG11201805941WA SG11201805941WA SG11201805941WA SG 11201805941W A SG11201805941W A SG 11201805941WA SG 11201805941W A SG11201805941W A SG 11201805941WA SG 11201805941W A SG11201805941W A SG 11201805941WA SG 11201805941W A SG11201805941W A SG 11201805941WA
- Authority
- SG
- Singapore
- Prior art keywords
- novartis
- international
- tgf
- massachusetts
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Abstract
met G.o1 1 iOa Yo966 .150 con& Imp . o MOR13434 • • 4Ent fate A •,,r.Z.11,9436. • (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2017/141208 Al 24 August 2017 (24.08.2017) WIPO I PCT (51) International Patent Classification: C07K 16/22 (2006.01) A61K 39/395 (2006.01) (21) International Application Number: PCT/IB2017/050917 (22) International Filing Date: 17 February 2017 (17.02.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/296,282 17 February 2016 (17.02.2016) US (71) Applicant: NOVARTIS AG [CH/CH]; Lichtstrasse 35, 4053 Basel (CH). (72) Inventors: IBEBUNJO, Chikwendu; Novartis Institutes for BioMedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts 02139 (US). JACOBI, Carsten; Novartis Pharma AG, Postfach, Novartis Insti- tutes for Biomed. Research, 4002 Basel (CH). MEYER, Angelika; Novartis Pharma AG, Postfach, Novartis Insti- tutes for Biomed. Research, 4002 Basel (CH). SCHAADT, Eveline; MORPHOSYS AG, Lena-Christ-Strasse 48, 82152 Planegg (DE). TRENDELENBURG, Anne-Ul- rike; Novartis Institutes for BioMedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts 02139 (US). VLADIMIROVNA MITINA, Olga; Morphosys AG, Lena-Christ-Strasse 48, 82152 Planegg (DE). (74) Agent: NOVARTIS AG; Lichtstrasse 35, 4053 (CH). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: — as to applicant's entitlement to apply for and be granted a patent (Rule 4.1700) Published: — with international search report (Art. 21(3)) [Continued on next page] = (54) Title: TGFBETA 2 ANTIBODIES Figure 3: Biologic activity and isoform-specificity by RGA activity (MOR13436) RGA:t9FDP40y t TGF4 it9A.PFOR:nti'GF-az 111111111111110111011111111111010111110 01011111011101011111110111111111110111111 W O 20 17 / 141208 Al o MOiR 1 S43 e CAT 15re g WS.V.2231 1 0.0691 0.0 -ipg 1 01196 Iii RsAloromap TGF-p! RIGA TaF-01 (57) : This invention is in the field of anti-transforming growth factor beta 2 (TGF-132) antibodies. In particular, the inven - tion provides human monoclonal antibodies that bind the human TGF-132 isoform preferentially over the human TGF-131 or TGF-133 isoforms. WO 2017/141208 Al 1#110HO1101DION01013010111101101011HOMOVOIMIE — with sequence listing part of description (Rule 5.2(a))
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662296282P | 2016-02-17 | 2016-02-17 | |
PCT/IB2017/050917 WO2017141208A1 (en) | 2016-02-17 | 2017-02-17 | Tgfbeta 2 antibodies |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201805941WA true SG11201805941WA (en) | 2018-09-27 |
Family
ID=58191507
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201805941WA SG11201805941WA (en) | 2016-02-17 | 2017-02-17 | Tgfbeta 2 antibodies |
Country Status (21)
Country | Link |
---|---|
US (1) | US11180546B2 (en) |
EP (1) | EP3416982A1 (en) |
JP (1) | JP2019511911A (en) |
KR (1) | KR20180107151A (en) |
CN (1) | CN108699142A (en) |
AU (1) | AU2017219254B2 (en) |
BR (1) | BR112018015690A2 (en) |
CA (1) | CA3012294A1 (en) |
CL (1) | CL2018001941A1 (en) |
CO (1) | CO2018008590A2 (en) |
CU (1) | CU20180088A7 (en) |
EA (1) | EA201891724A1 (en) |
EC (1) | ECSP18064646A (en) |
HK (1) | HK1257455A1 (en) |
IL (1) | IL261065A (en) |
MA (1) | MA44236A (en) |
MX (1) | MX2018010021A (en) |
PH (1) | PH12018501525A1 (en) |
RU (1) | RU2018131123A (en) |
SG (1) | SG11201805941WA (en) |
WO (1) | WO2017141208A1 (en) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201610044D0 (en) | 2016-06-08 | 2016-07-20 | Ucb Biopharma Sprl | Antibodies |
EP4007774A1 (en) | 2019-08-01 | 2022-06-08 | Vaccinex, Inc. | Combined inhibition of semaphorin-4d and tgfb and compositions therefor |
US11919948B2 (en) | 2020-03-19 | 2024-03-05 | Genentech, Inc. | Isoform-selective anti-TGFβ antibodies and methods of use |
CA3208365A1 (en) | 2021-02-15 | 2022-08-18 | Chantal KUHN | Cell therapy compositions and methods for modulating tgf-b signaling |
CN112940119B (en) * | 2021-04-26 | 2022-05-20 | 北京芳渟阳生生物科技有限公司 | Monoclonal antibody and combined application thereof and mesenchymal stem cell exosome |
WO2023201310A1 (en) | 2022-04-13 | 2023-10-19 | HCW Biologics, Inc. | Multi-chain chimeric polypeptide for use in the treatment of circardian clock gene disorder |
WO2023201311A1 (en) | 2022-04-13 | 2023-10-19 | HCW Biologics, Inc. | Multi-chain chimeric polypeptide for use in the treatment of treating neuroinflammatory disorder |
Family Cites Families (76)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4475196A (en) | 1981-03-06 | 1984-10-02 | Zor Clair G | Instrument for locating faults in aircraft passenger reading light and attendant call control system |
US4447233A (en) | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
US4439196A (en) | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
US4447224A (en) | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
US4487603A (en) | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
US4486194A (en) | 1983-06-08 | 1984-12-04 | James Ferrara | Therapeutic device for administering medicaments through the skin |
US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
US5374548A (en) | 1986-05-02 | 1994-12-20 | Genentech, Inc. | Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor |
MX9203291A (en) | 1985-06-26 | 1992-08-01 | Liposome Co Inc | LIPOSOMAS COUPLING METHOD. |
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
EP0307434B2 (en) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Altered antibodies |
US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
GB8809129D0 (en) | 1988-04-18 | 1988-05-18 | Celltech Ltd | Recombinant dna methods vectors and host cells |
US5571714A (en) * | 1988-12-22 | 1996-11-05 | Celtrix Pharmaceuticals, Inc. | Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
GB8905669D0 (en) | 1989-03-13 | 1989-04-26 | Celltech Ltd | Modified antibodies |
US5108921A (en) | 1989-04-03 | 1992-04-28 | Purdue Research Foundation | Method for enhanced transmembrane transport of exogenous molecules |
US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
GB9206861D0 (en) * | 1992-03-28 | 1992-05-13 | Univ Manchester | Wound healing and treatment of fibrotic disorders |
US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
PT1498427E (en) | 1992-08-21 | 2010-03-22 | Univ Bruxelles | Immunoglobulins devoid of light chains |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
GB9601081D0 (en) * | 1995-10-06 | 1996-03-20 | Cambridge Antibody Tech | Specific binding members for human transforming growth factor beta;materials and methods |
US7368111B2 (en) | 1995-10-06 | 2008-05-06 | Cambridge Antibody Technology Limited | Human antibodies specific for TGFβ2 |
US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
EP0983303B1 (en) | 1997-05-21 | 2006-03-08 | Biovation Limited | Method for the production of non-immunogenic proteins |
DK2180007T4 (en) | 1998-04-20 | 2017-11-27 | Roche Glycart Ag | Glycosylation technique for antibodies to enhance antibody-dependent cell cytotoxicity |
US6818418B1 (en) | 1998-12-10 | 2004-11-16 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
KR100940380B1 (en) | 1999-01-15 | 2010-02-02 | 제넨테크, 인크. | Polypeptide Variants with Altered Effector Function |
IL129299A0 (en) | 1999-03-31 | 2000-02-17 | Mor Research Applic Ltd | Monoclonal antibodies antigens and diagnosis of malignant diseases |
DK2270147T4 (en) | 1999-04-09 | 2020-08-31 | Kyowa Kirin Co Ltd | METHOD OF MONITORING THE ACTIVITY OF IMMUNOLOGICAL FUNCTIONAL MOLECULE |
EP1144607B1 (en) | 1999-07-20 | 2008-12-17 | MorphoSys AG | Methods for displaying (poly)peptides/proteins on bacteriophage particles via disulfide bonds |
JP2001206899A (en) | 1999-11-18 | 2001-07-31 | Japan Tobacco Inc | HUMAN MONOCLONAL ANTIBODY AGAINST TGF-beta II TYPE RECEPTOR AND MEDICINAL USE THEREOF |
US7943129B2 (en) | 2000-05-26 | 2011-05-17 | National Research Council Of Canada | Single-domain brain-targeting antibody fragments derived from llama antibodies |
ES2330330T3 (en) | 2000-06-28 | 2009-12-09 | Glycofi, Inc. | PROCEDURE OF PRODUCTION OF MODIFIED GLUCOPROTEINS. |
US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
CN100423777C (en) | 2001-10-25 | 2008-10-08 | 杰南技术公司 | Glycoprotein compositions |
IL149820A0 (en) | 2002-05-23 | 2002-11-10 | Curetech Ltd | Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency |
CN101899114A (en) | 2002-12-23 | 2010-12-01 | 惠氏公司 | Anti-PD-1 antibody and uses thereof |
BRPI0608376A8 (en) | 2005-04-22 | 2018-10-16 | Lilly Co Eli | binding composition, method of using a binding composition, and detection kit |
PL2439273T3 (en) | 2005-05-09 | 2019-08-30 | Ono Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics |
ES2526705T3 (en) | 2005-10-25 | 2015-01-14 | The Johns Hopkins University | Methods and compositions for the treatment of Marfan syndrome and associated disorders |
EP2170959B1 (en) | 2007-06-18 | 2013-10-02 | Merck Sharp & Dohme B.V. | Antibodies to human programmed death receptor pd-1 |
US20090087443A1 (en) * | 2007-09-27 | 2009-04-02 | Bartels Stephen P | Pharmacological Adjunctive Treatment Associated with Glaucoma Filtration Surgery |
EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | Pd-1 binding proteins |
KR20110074850A (en) | 2008-08-25 | 2011-07-04 | 앰플리뮨, 인크. | Pd-1 antagonists and methods of use thereof |
AU2009290544B2 (en) | 2008-09-12 | 2015-07-16 | Oxford University Innovation Limited | PD-1 specific antibodies and uses thereof |
AU2009296392B2 (en) | 2008-09-26 | 2016-06-02 | Dana-Farber Cancer Institute, Inc. | Human anti-PD-1, PD-L1, and PD-L2 antibodies and uses therefor |
NO2424895T3 (en) | 2009-04-27 | 2018-02-03 | ||
US20130017199A1 (en) | 2009-11-24 | 2013-01-17 | AMPLIMMUNE ,Inc. a corporation | Simultaneous inhibition of pd-l1/pd-l2 |
CA2791930A1 (en) | 2010-03-11 | 2011-09-15 | Kerry Louise Tyson | Pd-1 antibody |
US8907053B2 (en) | 2010-06-25 | 2014-12-09 | Aurigene Discovery Technologies Limited | Immunosuppression modulating compounds |
US8800906B2 (en) | 2010-12-27 | 2014-08-12 | The Board Of Trustees Of The Leland Stanford Junior University | Use of transforming growth factor-beta neutralizing antibodies and fusion proteins thereof in treating pain |
DK2699264T3 (en) | 2011-04-20 | 2018-06-25 | Medimmune Llc | ANTIBODIES AND OTHER MOLECULES BINDING B7-H1 AND PD-1 |
HRP20211582T1 (en) * | 2011-06-03 | 2022-01-07 | Xoma Technology Ltd. | Antibodies specific for tgf-beta |
RU2604814C2 (en) | 2011-07-24 | 2016-12-10 | Кьюртек Лтд. | Versions of humanized immunomodulatory monoclonal antibodies |
LT2992017T (en) | 2013-05-02 | 2021-02-25 | Anaptysbio, Inc. | Antibodies directed against programmed death-1 (pd-1) |
WO2014194302A2 (en) | 2013-05-31 | 2014-12-04 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind pd-1 |
US20160145355A1 (en) | 2013-06-24 | 2016-05-26 | Biomed Valley Discoveries, Inc. | Bispecific antibodies |
CN112552401B (en) | 2013-09-13 | 2023-08-25 | 广州百济神州生物制药有限公司 | anti-PD 1 antibodies and their use as therapeutic and diagnostic agents |
ME03527B (en) | 2013-12-12 | 2020-04-20 | Shanghai hengrui pharmaceutical co ltd | Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof |
TWI681969B (en) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | Human antibodies to pd-1 |
JOP20200094A1 (en) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | Antibody molecules to pd-1 and uses thereof |
TWI693232B (en) | 2014-06-26 | 2020-05-11 | 美商宏觀基因股份有限公司 | Covalently bonded diabodies having immunoreactivity with pd-1 and lag-3, and methods of use thereof |
TWI595006B (en) | 2014-12-09 | 2017-08-11 | 禮納特神經系統科學公司 | Anti-pd-1 antibodies and methods of use thereof |
-
2017
- 2017-02-17 MA MA044236A patent/MA44236A/en unknown
- 2017-02-17 BR BR112018015690A patent/BR112018015690A2/en not_active IP Right Cessation
- 2017-02-17 AU AU2017219254A patent/AU2017219254B2/en not_active Ceased
- 2017-02-17 MX MX2018010021A patent/MX2018010021A/en unknown
- 2017-02-17 US US15/999,368 patent/US11180546B2/en active Active
- 2017-02-17 WO PCT/IB2017/050917 patent/WO2017141208A1/en active Application Filing
- 2017-02-17 CA CA3012294A patent/CA3012294A1/en not_active Abandoned
- 2017-02-17 EP EP17707960.5A patent/EP3416982A1/en not_active Withdrawn
- 2017-02-17 EA EA201891724A patent/EA201891724A1/en unknown
- 2017-02-17 CU CU2018000088A patent/CU20180088A7/en unknown
- 2017-02-17 CN CN201780011724.8A patent/CN108699142A/en active Pending
- 2017-02-17 KR KR1020187023260A patent/KR20180107151A/en unknown
- 2017-02-17 JP JP2018543390A patent/JP2019511911A/en not_active Ceased
- 2017-02-17 SG SG11201805941WA patent/SG11201805941WA/en unknown
- 2017-02-17 RU RU2018131123A patent/RU2018131123A/en not_active Application Discontinuation
-
2018
- 2018-07-16 PH PH12018501525A patent/PH12018501525A1/en unknown
- 2018-07-18 CL CL2018001941A patent/CL2018001941A1/en unknown
- 2018-08-08 IL IL261065A patent/IL261065A/en unknown
- 2018-08-15 CO CONC2018/0008590A patent/CO2018008590A2/en unknown
- 2018-08-27 EC ECSENADI201864646A patent/ECSP18064646A/en unknown
- 2018-12-28 HK HK18116690.9A patent/HK1257455A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
KR20180107151A (en) | 2018-10-01 |
PH12018501525A1 (en) | 2019-03-18 |
EP3416982A1 (en) | 2018-12-26 |
CU20180088A7 (en) | 2019-05-03 |
CA3012294A1 (en) | 2017-08-24 |
WO2017141208A1 (en) | 2017-08-24 |
AU2017219254A1 (en) | 2018-08-02 |
CO2018008590A2 (en) | 2018-08-21 |
JP2019511911A (en) | 2019-05-09 |
IL261065A (en) | 2018-10-31 |
MA44236A (en) | 2018-12-26 |
RU2018131123A (en) | 2020-03-17 |
HK1257455A1 (en) | 2019-10-18 |
ECSP18064646A (en) | 2018-09-30 |
BR112018015690A2 (en) | 2018-12-26 |
AU2017219254B2 (en) | 2019-12-12 |
CN108699142A (en) | 2018-10-23 |
MX2018010021A (en) | 2018-11-09 |
US20190092846A1 (en) | 2019-03-28 |
EA201891724A1 (en) | 2019-01-31 |
RU2018131123A3 (en) | 2020-07-09 |
US11180546B2 (en) | 2021-11-23 |
CL2018001941A1 (en) | 2018-09-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201805941WA (en) | Tgfbeta 2 antibodies | |
SG11201903454VA (en) | Immunologically discernible cell surface variants for use in cell therapy | |
SG11201906431UA (en) | Method for the treatment of thromboembolism | |
SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
SG11201804161VA (en) | Compositions comprising bacterial strains | |
SG11201810420YA (en) | Antibodies to alpha-synuclein and uses thereof | |
SG11201806261XA (en) | Bcma antibodies and use of same to treat cancer and immunological disorders | |
SG11201805044WA (en) | Compounds useful as kinase inhibitors | |
SG11201807176XA (en) | TGFß1-BINDING IMMUNOGLOBULINS AND USE THEREOF | |
SG11201810371XA (en) | ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF | |
SG11201907804QA (en) | Pharmaceutical composition comprising selexipag | |
SG11201808566WA (en) | Polymorphic form of n-{6-(2-hydroxypropan-2-yl)-2-[2-(methylsulphonyl)ethyl]-2h-indazol-5-yl}-6-(trifluoromethyl)pyridine-2-carboxamide | |
SG11201805311XA (en) | Method of treating a mammal, including human, against cancer using methionine and asparagine depletion | |
SG11201910134SA (en) | Stable formulations of anti-ctla4 antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof | |
SG11201808539WA (en) | Mouth piece for cooling of oral tissue of a patient during chemotherapy treatment | |
SG11201807827VA (en) | Process for the preparation of pegylated drug-linkers and intermediates thereof | |
SG11201808106YA (en) | Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation | |
SG11201903061YA (en) | Combination treatments comprising administration of imidazopyrazinones | |
SG11201900405XA (en) | Compounds, compositions and methods for treating or preventing a sympton associated with gout or hyperuricemia | |
SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
SG11202000333UA (en) | Bicyclic ketone compounds and methods of use thereof | |
SG11201806544XA (en) | Compounds and methods of treating rna-mediated diseases | |
SG11201809764XA (en) | Humanized anti-il-1r3 antibodies | |
SG11201908980PA (en) | Treatment using chimeric receptor t cells incorporating optimized polyfunctional t cells |